Janssen: The Janssen Pharmaceutical Companies of Johnson & Johnson ranks #4 with a brand value of USD $13.866 billion. Janssen focuses on five therapeutic areas: cardiovascular and metabolism, immunology, infectious diseases and vaccines, neuroscience, and oncology.
The Janssen corporate brand performed well above the industry benchmark in its impact on healthcare professional (HCP) decision-making; our hypothesis is that this may be driven by Janssen being part of the Johnson & Johnson family of Companies.
Janssen’s mission is to, “Transform individual lives and fundamentally change the way diseases are managed, interpreted, and prevented.” HCPs confirmed that Janssen is delivering on this promise, recognizing the company for delivering outstanding healthcare solutions, using a patient-centric approach.
Janssen is viewed as a company that consistently focuses on and invests in building strong relationships with HCPs while continually pushing the boundaries of what is possible in healthcare. Today, Janssen also gets recognition from HCPs for its dedication to science and discovery research in service of improving patient outcomes.